Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 3, 2014, Pages 478-483

  Medjeral Thomas, Nicholas ^a   Ziaj, Stela ^a   Condon, Marie ^a   Galliford, Jack ^a   Levy, Jeremy ^a   Cairns, Tom ^a   Griffith, Megan ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; SERUM ALBUMIN; WARFARIN;

ADULT; AGED; ARTICLE; CREATININE URINE LEVEL; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PROTEIN URINE LEVEL; PROTEINURIA; RETROSPECTIVE STUDY; RISK FACTOR; VENOUS THROMBOEMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; BIOLOGICAL MARKERS; FEMALE; FIBRINOLYTIC AGENTS; GLOMERULONEPHRITIS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LONDON; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WARFARIN; YOUNG ADULT;

EID: 84896859518     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07190713     Document Type: Article

References (20)

1. Fervenza FC, Sethi S, Specks U: Idiopathic membranous nephropathy: Diagnosis and treatment. Clin J Am Soc Nephrol 3: 905-919, 2008.
2. Orth SR, Ritz E: The nephrotic syndrome. N Engl J Med 338: 1202-1211, 1998.
3. Kerlin BA, Ayoob R, Smoyer WE: Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol 7: 513-520, 2012.
4. Mahmoodi BK, ten Kate MK, Waanders F, Veeger NJGM, Brouwer J-LP, Vogt L, Navis G, van der Meer J: High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: Results from a large retrospective cohort study. Circulation 117: 224-230, 2008.
5. Kato S, Chernyavsky S, Tokita JE, Shimada YJ, Homel P, Rosen H, Winchester JF: Relationship between proteinuria and venous thromboembolism. J Thromb Thrombolysis 30: 281-285, 2010.
6. Glassock RJ: Prophylactic anticoagulation in nephrotic syndrome: A clinical conundrum. J Am Soc Nephrol 18: 2221-2225, 2007.
7. Lionaki S, Derebail V, Hogan SL, Barbour S, Lee T, Hladunewich M, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, NachmanPH, ReichHN:Venous Thromboembolism in patientswith membranous nephropathy. Clin J Am Soc Nephrol 7: 43-51, 2012.
8. Barbour SJ, Greenwald A, Djurdjev O, Levin A, Hladunewich MA, Nachman PH, Hogan SL, Cattran DC, Reich HN: Diseasespecific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int 81: 190-195, 2012.
9. Li S-J, Guo J-Z, Zuo K, Zhang J, Wu Y, Zhou CS, Lu GM, Liu ZH: Thromboembolic complications in membranous nephropathy patients with nephrotic syndrome-a prospective study. Thromb Res 130: 501-505, 2012.
10. Bellomo R, Atkins RC: Membranous nephropathy and thromboembolism: Is prophylactic anticoagulation warranted? Nephron 63: 249-254, 1993.
11. Sarasin FP, Schifferli JA: Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 45: 578-585, 1994.
12. Leizorovicz A, Mismetti P: Preventing venous thromboembolism in medical patients. Circulation 110[Suppl 1]: IV13-IV19, 2004.
13. Samama MM, Cohen AT, Darmon J-Y, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N; Prophylaxis in Medical Patients with Enoxaparin Study Group: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 341: 793-800, 1999.
14. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA: Metaanalysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 146: 278-288, 2007.
15. Sandercock PAGCC, Counsell C, Kamal AK: Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev (4): CD000024, 2008. 10.1002/14651858.CD000024.pub3.
16. Singhal R, Brimble KS: Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res 118: 397-407, 2006.
17. Antithrombotic Trialists' Collaboration: Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86, 2002.
18. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, Bianchi M, Moia M, Ageno W, Vandelli MR, Grandone E, Prandoni P; WARFASA Investigators: Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 366: 1959-1967, 2012.
19. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J; ASPIRE Investigators: Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 367: 1979- 1987, 2012.
20. Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E: Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: Systematic review, meta-analysis, and indirect treatment comparisons. BMJ 344: e3675, 2012